Trial Profile
Strategic Trial for the Prevention of Progression of Overt Diabetic Kidney Disease by GLP-1receptor agonists and SGLT2 inhibitors in Okinawa
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Liraglutide (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms STOPPER
- 08 Sep 2018 Status changed from not yet recruiting to recruiting.
- 04 Apr 2018 New trial record